S.4257 (Resources To Prevent Youth Vaping Act) imposes a direct 16% increase in FDA tobacco user fees from $712M to $826.2M in FY2027, with CPI-indexed increases and fee base expansion to include e-cigarettes and heated tobacco by FY2029. $MO is the most directly affected — faces ~$114M in new annual costs. $PM faces indirect regulatory signal risk. This is early-stage legislation (referred to committee); no immediate market impact, but monitoring is warranted as the 16% fee hike is the largest single-year increase in the program's history.
→ By FY2029, IQOS heated tobacco units will be included in FDA user fee allocation. This adds incremental cost to Altria's distribution of IQOS in the US, which may be partially passed back to PM via contract terms. The total fee increase across all products is $114.2M in FY2027 plus CPI escalators, but the allocation to IQOS specifically is indeterminate until final fee allocation rules are issued by FDA.